Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika.

Erasmus JH, Khandhar AP, Guderian J, Granger B, Archer J, Archer M, Gage E, Fuerte-Stone J, Larson E, Lin S, Kramer R, Coler RN, Fox CB, Stinchcomb DT, Reed SG, Van Hoeven N.

Mol Ther. 2018 Oct 3;26(10):2507-2522. doi: 10.1016/j.ymthe.2018.07.010. Epub 2018 Aug 2.

PMID:
30078765
2.

Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica.

Abhyankar MM, Orr MT, Lin S, Suraju MO, Simpson A, Blust M, Pham T, Guderian JA, Tomai MA, Elvecrog J, Pedersen K, Petri WA Jr, Fox CB.

NPJ Vaccines. 2018 Jun 5;3:22. doi: 10.1038/s41541-018-0060-x. eCollection 2018.

3.

Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.

Baldwin SL, Hsu FC, Van Hoeven N, Gage E, Granger B, Guderian JA, Larsen SE, Lorenzo EC, Haynes L, Reed SG, Coler RN.

Front Immunol. 2018 Feb 19;9:295. doi: 10.3389/fimmu.2018.00295. eCollection 2018.

4.

A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.

Duthie MS, Pereira L, Favila M, Hofmeyer KA, Reed SJ, Metangmo S, Townsend S, Laurance JD, Picone A, Misquith A, Hossain F, Ghosh P, Khan MAA, Guderian J, Bailor HR, Liang H, Vergara J, Oliveira F, Howard RF, Kamhawi S, Mondal D, Coler RN, Valenzuela JG, Reed SG.

NPJ Vaccines. 2017 Aug 21;2:23. doi: 10.1038/s41541-017-0025-5. eCollection 2017.

5.

A structure-function approach to optimizing TLR4 ligands for human vaccines.

Carter D, Fox CB, Day TA, Guderian JA, Liang H, Rolf T, Vergara J, Sagawa ZK, Ireton G, Orr MT, Desbien A, Duthie MS, Coler RN, Reed SG.

Clin Transl Immunology. 2016 Nov 2;5(11):e108. eCollection 2016 Nov.

6.

Use of Recombinant Antigens for Sensitive Serodiagnosis of American Tegumentary Leishmaniasis Caused by Different Leishmania Species.

Sato CM, Sanchez MC, Celeste BJ, Duthie MS, Guderian J, Reed SG, de Brito ME, Campos MB, de Souza Encarnação HV, Guerra J, de Mesquita TG, Pinheiro SK, Ramasawmy R, Silveira FT, de Assis Souza M, Goto H.

J Clin Microbiol. 2017 Feb;55(2):495-503. doi: 10.1128/JCM.01904-16. Epub 2016 Dec 7.

7.

Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii.

El Bissati K, Chentoufi AA, Krishack PA, Zhou Y, Woods S, Dubey JP, Vang L, Lykins J, Broderick KE, Mui E, Suzuki Y, Sa Q, Bi S, Cardona N, Verma SK, Frazeck L, Reardon CA, Sidney J, Alexander J, Sette A, Vedvick T, Fox C, Guderian JA, Reed S, Roberts CW, McLeod R.

JCI Insight. 2016 Sep 22;1(15):e85955. doi: 10.1172/jci.insight.85955.

8.

Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis.

Duthie MS, Favila M, Hofmeyer KA, Tutterrow YL, Reed SJ, Laurance JD, Picone A, Guderian J, Bailor HR, Vallur AC, Liang H, Mohamath R, Vergara J, Howard RF, Coler RN, Reed SG.

Vaccine. 2016 May 27;34(25):2779-86. doi: 10.1016/j.vaccine.2016.04.067. Epub 2016 May 1.

9.

Multi-epitope proteins for improved serological detection of Trypanosoma cruzi infection and Chagas Disease.

Duthie MS, Guderian JA, Vallur AC, Misquith A, Liang H, Mohamath R, Luquetti AO, Carter D, Tavares SN, Reed SG.

Diagn Microbiol Infect Dis. 2016 Mar;84(3):191-6. doi: 10.1016/j.diagmicrobio.2015.11.006. Epub 2015 Nov 10.

PMID:
26658314
10.

Molecular Design of Squalene/Squalane Countertypes via the Controlled Oligomerization of Isoprene and Evaluation of Vaccine Adjuvant Applications.

Adlington K, El Harfi J, Li J, Carmichael K, Guderian JA, Fox CB, Irvine DJ.

Biomacromolecules. 2016 Jan 11;17(1):165-72. doi: 10.1021/acs.biomac.5b01285. Epub 2015 Dec 29.

PMID:
26652915
11.

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.

Coler RN, Duthie MS, Hofmeyer KA, Guderian J, Jayashankar L, Vergara J, Rolf T, Misquith A, Laurance JD, Raman VS, Bailor HR, Cauwelaert ND, Reed SJ, Vallur A, Favila M, Orr MT, Ashman J, Ghosh P, Mondal D, Reed SG.

Clin Transl Immunology. 2015 Apr 10;4(4):e35. doi: 10.1038/cti.2015.6. eCollection 2015 Apr.

12.

A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7.

Fox CB, Sivananthan SJ, Duthie MS, Vergara J, Guderian JA, Moon E, Coblentz D, Reed SG, Carter D.

J Nanobiotechnology. 2014 Apr 26;12:17. doi: 10.1186/1477-3155-12-17.

13.

Modulating potency: Physicochemical characteristics are a determining factor of TLR4-agonist nanosuspension activity.

Dowling QM, Sivananthan SJ, Guderian JA, Moutaftsi M, Chesko JD, Fox CB, Vedvick TS, Kramer RM.

J Pharm Sci. 2014 Mar;103(3):879-89. doi: 10.1002/jps.23868. Epub 2014 Jan 24.

PMID:
24464844
14.

Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity.

Fung HW, Mikasa TJ, Vergara J, Sivananthan SJ, Guderian JA, Duthie MS, Vedvick TS, Fox CB.

J Nanobiotechnology. 2013 Dec 21;11:43. doi: 10.1186/1477-3155-11-43.

15.

Early experience with a brief, multimodal, multidisciplinary treatment program for fibromyalgia.

Vincent A, Whipple MO, Oh TH, Guderian JA, Barton DL, Luedtke CA.

Pain Manag Nurs. 2013 Dec;14(4):228-235. doi: 10.1016/j.pmn.2011.05.001. Epub 2011 Jul 2.

16.

Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.

Duthie MS, Guderian J, Vallur A, Bhatia A, Lima dos Santos P, Vieira de Melo E, Ribeiro de Jesus A, Todt M, Mondal D, Almeida R, Reed SG.

Eur J Clin Microbiol Infect Dis. 2014 Apr;33(4):639-49. doi: 10.1007/s10096-013-1999-1. Epub 2013 Oct 31.

17.

In vitro evaluation of TLR4 agonist activity: formulation effects.

Misquith A, Fung HW, Dowling QM, Guderian JA, Vedvick TS, Fox CB.

Colloids Surf B Biointerfaces. 2014 Jan 1;113:312-9. doi: 10.1016/j.colsurfb.2013.09.006. Epub 2013 Sep 19.

18.

High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasis.

de Oliveira FA, Vanessa Oliveira Silva C, Damascena NP, Passos RO, Duthie MS, Guderian JA, Bhatia A, de Moura TR, Reed SG, de Almeida RP, de Jesus AR.

BMC Infect Dis. 2013 Jul 19;13:331. doi: 10.1186/1471-2334-13-331.

19.

MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.

Orr MT, Duthie MS, Windish HP, Lucas EA, Guderian JA, Hudson TE, Shaverdian N, O'Donnell J, Desbien AL, Reed SG, Coler RN.

Eur J Immunol. 2013 Sep;43(9):2398-408. doi: 10.1002/eji.201243124. Epub 2013 Jul 3.

20.

Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay.

Ching LK, Mompoint F, Guderian JA, Picone A, Orme IM, Coler RN, Reed SG, Baldwin SL.

J Immunol Methods. 2011 Oct 28;373(1-2):54-62. doi: 10.1016/j.jim.2011.07.021. Epub 2011 Aug 3.

21.

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, Laughlin EM, Duthie MS, Fox CB, Carter D, Friede M, Vedvick TS, Reed SG.

PLoS One. 2011 Jan 26;6(1):e16333. doi: 10.1371/journal.pone.0016333.

22.

Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis.

Pattabhi S, Whittle J, Mohamath R, El-Safi S, Moulton GG, Guderian JA, Colombara D, Abdoon AO, Mukhtar MM, Mondal D, Esfandiari J, Kumar S, Chun P, Reed SG, Bhatia A.

PLoS Negl Trop Dis. 2010 Sep 14;4(9). pii: e822. doi: 10.1371/journal.pntd.0000822.

23.

Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis.

Raman VS, Bhatia A, Picone A, Whittle J, Bailor HR, O'Donnell J, Pattabhi S, Guderian JA, Mohamath R, Duthie MS, Reed SG.

J Immunol. 2010 Aug 1;185(3):1701-10. doi: 10.4049/jimmunol.1000238. Epub 2010 Jul 2.

24.

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral-Sampaio G, de Jesus RS, Goto Y, Guderian J, Howard RF, Reed SG.

Vaccine. 2010 Apr 26;28(19):3333-40. doi: 10.1016/j.vaccine.2010.02.089. Epub 2010 Mar 4.

25.

Upregulated expression of B-cell antigen family tandem repeat proteins by Leishmania amastigotes.

Goto Y, Carter D, Guderian J, Inoue N, Kawazu S, Reed SG.

Infect Immun. 2010 May;78(5):2138-45. doi: 10.1128/IAI.01102-09. Epub 2010 Feb 16.

26.

Lateral flow immunoassay for diagnosis of Trypanosoma cruzi infection with high correlation to the radioimmunoprecipitation assay.

Houghton RL, Stevens YY, Hjerrild K, Guderian J, Okamoto M, Kabir M, Reed SG, Leiby DA, Morrow WJ, Lorca M, Raychaudhuri S.

Clin Vaccine Immunol. 2009 Apr;16(4):515-20. doi: 10.1128/CVI.00383-08. Epub 2009 Feb 11.

27.

Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis.

Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, Laughlin EM, Baldwin SL, Vedvick TS, Coler RN, Reed SG.

J Immunol. 2008 Dec 1;181(11):7948-57.

28.

Variable expression of immunoreactive surface proteins of Propionibacterium acnes.

Lodes MJ, Secrist H, Benson DR, Jen S, Shanebeck KD, Guderian J, Maisonneuve JF, Bhatia A, Persing D, Patrick S, Skeiky YA.

Microbiology. 2006 Dec;152(Pt 12):3667-81.

PMID:
17159220
29.

Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins.

Goto Y, Coler RN, Guderian J, Mohamath R, Reed SG.

Infect Immun. 2006 Jul;74(7):3939-45.

30.

ML0405 and ML2331 are antigens of Mycobacterium leprae with potential for diagnosis of leprosy.

Reece ST, Ireton G, Mohamath R, Guderian J, Goto W, Gelber R, Groathouse N, Spencer J, Brennan P, Reed SG.

Clin Vaccine Immunol. 2006 Mar;13(3):333-40.

31.

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein.

Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, Campos-Neto A, Lobet Y, Dalemans W, Orme IM, Reed SG.

J Immunol. 2004 Jun 15;172(12):7618-28.

32.

A novel method for increasing the expression level of recombinant proteins.

Wang A, Clapper J, Guderian JA, Foy TM, Fanger GR, Retter MW, Skeiky YA.

Protein Expr Purif. 2003 Jul;30(1):124-33.

PMID:
12821330
33.

Cloning of a Mycobacterium tuberculosis gene encoding a purifed protein derivative protein that elicits strong tuberculosis-specific delayed-type hypersensitivity.

Coler RN, Skeiky YA, Ovendale PJ, Vedvick TS, Gervassi L, Guderian J, Jen S, Reed SG, Campos-Neto A.

J Infect Dis. 2000 Jul;182(1):224-33. Epub 2000 Jul 6.

PMID:
10882601
34.

Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis.

Skeiky YA, Lodes MJ, Guderian JA, Mohamath R, Bement T, Alderson MR, Reed SG.

Infect Immun. 1999 Aug;67(8):3998-4007.

35.

LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.

Skeiky YA, Kennedy M, Kaufman D, Borges MM, Guderian JA, Scholler JK, Ovendale PJ, Picha KS, Morrissey PJ, Grabstein KH, Campos-Neto A, Reed SG.

J Immunol. 1998 Dec 1;161(11):6171-9.

36.

Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis.

Webb JR, Vedvick TS, Alderson MR, Guderian JA, Jen SS, Ovendale PJ, Johnson SM, Reed SG, Skeiky YA.

Infect Immun. 1998 Sep;66(9):4208-14.

37.

Onchocerciasis in Ecuador: prevalence of infection on the Ecuador-Colombia border in the Province of Esmeraldas.

Guderian JR, Anselmi M, Espinel M, Sandoval C, Cooper PJ, Rivadeneira G, Guderian RH.

Mem Inst Oswaldo Cruz. 1997 Mar-Apr;92(2):157-62.

38.

Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans.

Skeiky YA, Benson DR, Guderian JA, Whittle JA, Bacelar O, Carvalho EM, Reed SG.

Infect Immun. 1995 Oct;63(10):4105-14.

39.

A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.

Skeiky YA, Guderian JA, Benson DR, Bacelar O, Carvalho EM, Kubin M, Badaro R, Trinchieri G, Reed SG.

J Exp Med. 1995 Apr 1;181(4):1527-37.

40.

Trypanosoma cruzi acidic ribosomal P protein gene family. Novel P proteins encoding unusual cross-reactive epitopes.

Skeiky YA, Benson DR, Guderian JA, Sleath PR, Parsons M, Reed SG.

J Immunol. 1993 Nov 15;151(10):5504-15.

PMID:
7693813
41.

Trypanosoma brucei minicircles encode multiple guide RNAs which can direct editing of extensively overlapping sequences.

Corell RA, Feagin JE, Riley GR, Strickland T, Guderian JA, Myler PJ, Stuart K.

Nucleic Acids Res. 1993 Sep 11;21(18):4313-20.

42.

Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia.

Loughran TP Jr, Zambello R, Ashley R, Guderian J, Pellenz M, Semenzato G, Starkebaum G.

Blood. 1993 May 15;81(10):2723-7.

Supplemental Content

Loading ...
Support Center